CSBTF (Kuros Biosciences) DeferredTaxAndRevenue: $0.0 Mil (As of Dec. 2025)


CSBTF Kuros Biosciences Ltd CSBTF
71 GF Score
Price $22.72
GF Value $54.94
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences DeferredTaxAndRevenue?

Kuros Biosciences CSBTF 71 DeferredTaxAndRevenue is $0.0 Mil as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.94 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Kuros Biosciences's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.0 Mil.

Kuros Biosciences DeferredTaxAndRevenue Related Terms

Kuros Biosciences DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Kuros Biosciences's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences DeferredTaxAndRevenue Chart

Kuros Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kuros Biosciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CSBTF
71GF Score
Kuros Biosciences Ltd CSBTF
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.0 Mil mean?
Kuros Biosciences (CSBTF) has a DeferredTaxAndRevenue of $0.0 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Kuros Biosciences.
Is Kuros Biosciences' DeferredTaxAndRevenue too high?
Kuros Biosciences' current DeferredTaxAndRevenue is $0.0 Mil. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' DeferredTaxAndRevenue compare to ABT and SYK?
Kuros Biosciences' DeferredTaxAndRevenue of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Devices & Instruments company?
A good DeferredTaxAndRevenue depends on the Medical Devices & Instruments industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Kuros Biosciences. Kuros Biosciences's current DeferredTaxAndRevenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.94, compared to a current price of $22.72 — trading 58.6% below its estimated fair value. The current DeferredTaxAndRevenue is $0.0 Mil. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current DeferredTaxAndRevenue is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $22.72 is trading 58.6% below its estimated GF Value™ of $54.94. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • DeferredTaxAndRevenue: $0.0 Mil
  • GF Value™: $54.94 vs. price of $22.72 (58.6% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score

Get the complete analysis for CSBTF

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.72
Price
$54.94
GF Value